{"anticipatedPostingDate":"2017-10","denomUnitsSelected":"Participants","description":"Compare overall response rate \\[combined CR + very good partial response (VGPR) + PR + MR\\] and disease parameters \\[time to progression, -progression free survival, -time to first response, -duration of response, -overall survival\\] following treatment with a SC bortezomib-containing combination regimen for MM patients who have demonstrated progressive disease form a prior or different IV bortezomib-containing combination regimen. Determine incidence and severity of injection-site reactions with CS administration of bortezomib by number of patients with injection site reaction specific adverse events.","reportingStatus":"NOT_POSTED","timeFrame":"Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28 day treatment cycles.","title":"Compare Overall Response Rate (CR + VGPR + PR + MR), Compare Disease Parameters, & Determine Incidence and Severity of Injection-site Reactions.","type":"SECONDARY"}